PubMed · 2019 · 16 citations · 24 references
Open access
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyGenitourinary Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyProstate CancerTargeted Cancer TherapyTargeted TherapyAdvanced Prostate Cancer TherapyAndrogen Receptor ExpressionAndrogen Receptor TargetingAnti-androgen ResistanceCastration-resistant Prostate Cancer TherapyEpithelial-mesenchymal Transition MarkersMesenchymal TransitionProstate Cancer Hormonal Therapy
BACKGROUND: models of advanced prostate cancer and the ability of the compound to overcome resistance to antiandrogen (enzalutamide) in prostate tumors. APPROACH: LNCaP and LNCaP-enzalutamide resistant human prostate cancer (LNCaP-ER) cells, as well as 22Rv1 and enzalutamide resistant, 22Rv1-ER were used as cell models. The effects of DZ-50 and the antiandrogen, enzalutamide (as single agents or in combination) on cell death, EMT-MET interconversion, and expression of IGFBP3 and the androgen receptor (AR), were examined. The TRAMP mouse model of prostate cancer progression was used as a pre-clinical model. Transgenic mice (20-wks of age) were treated with DZ-50 (100 mg/kg for 2 wks, oral gavage daily) and prostate tumors were subjected to immunohistochemical assessment of apoptosis, cell proliferation, markers of EMT and differentiation and IGFBP-3 and AR expression. A tissue microarray (TMA) was analyzed for expression of IGBP-3, the target of DZ-50 and its association with tumor progression and biochemical recurrence. RESULTS: , by targeting nuclear IGFBP-3 expression (without affecting AR). Analysis of human prostate cancer specimens and TCGA patient cohorts revealed that overexpression of IGBP-3 protein correlated with tumor recurrence and poor patient survival. CONCLUSIONS: These findings provide significant new insights into (a) the predictive value of IGFBP-3 in prostate cancer progression and (b) the antitumor action of DZ-50, [in combination or sequencing with enzalutamide] as a novel approach for the treatment of therapeutically resistant prostate cancer.
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus et al. · Cancer Cell · 2010 · 3.8K citations · Full text
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · Nature · 2012 · 2.6K citations